0435-5088008
Contact:
4008465777
×
-
About Us
News & Events
-
04-29Tonghua Dongbao's Q1 earnings double with a net profit attributable to parent of RMB 831 million On the evening of April 28, Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao") released its quarterly report for Q1 2022. Specifically, the revenue hit RMB 887 million, up 7...
-
04-26Tonghua Dongbao: First subject enrolled in phase I clinical trial of novel URAT1 inhibitor (THDBH130 Tablets) in China In December 2021, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. ("Dongbao Zixing"), a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao") r...
-
04-20Tonghua Dongbao 2021 results: Net profit attributable to parent up 40.69% YoY On the evening of April 18, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its annual report for 2021. In 2021, t...
-
04-12Tonghua Dongbao: Phase I clinical trial application for BC Combo approved in Germany Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") was approved by the Federal Institute for Drugs and Medical Devices (BfArM) in Germany for the phase I clinical trial of B...
-
03-18Tonghua Dongbao sells some of its shares in Amoytop again to accelerate innovation and R&D On March 17, 2022, Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") announced its plan to transfer 20.5 million shares (or 5.04% of total share capital) in Xiamen Amoytop ...
-
03-11Tonghua Dongbao: Clinical trial application for BC Combo approved Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") received the notification of approval (No. 2022LP00393) from the National Medical Products Administration (NMPA) on the clinical trial application for BC Combo (THDB0207 injection), a soluble insulin glargine and insulin lispro injection. The acceptance number is CXSL210151.